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Fetal and Neonatal Hypoglycemia
M. Cornblath
1.0 Introductlon to General Topic
Although blood sugars have been measured in newborn infants
since 1910, 1t was 1929 before Von Creveld reported blood sugar
levels in low birth weight neonates were lower than those in term
or öl der infants and children. Over the next 30 years, sporadic
reports of newborn infants with profound, severe or recurrent
hypoglycemia appeared including the classical reports of Hartmann
and Jaudon in 1937, and McQuarrie in 1952. However, since 1959,
with the recognition of transient symptomatic hypoglycemia in the
small for gestational age (SGA) male infant, hypoglycemia has been
recognized äs a frequent problem in neonatal care (1). In
addition, studies have provided a definition of normal and
abnormal glucose values in blood in both fül l sized and low-birth
weight infants, äs well äs a better understanding of glucose
transport across the placenta and fetal physiology (2) . In 1981,
the modern era of understanding fetal and perinatal carbohydrate
endocrinology and metabolism has arrived.
Thus, it i s now known that size at birth and growth in utero
depend upon fetal Insul in secretion äs well äs availabil i ty "ÖT
maternal Substrates. Hypoglycemia occurs in 3 to 4 infants per
1000 live births, may be symptomatic or asymptomatic, and can
produce severe sequelae, even death, if unrecognized or untreated.
A distinguished group of colleagues will present the current
Status of important aspects of hypoglyemica in the fetus and
neonate. First: Professor Karl i s Adamson, "In Utero" Events,
from both a Theoretical and Clinical Point of View; then, Dr.
Ingeborg Brandt, "The Frequency and Importance of Hypoglycemia in
the Neonate"; third, Professor Petter Karlberg, "Metabolie Aspects
of Care of Neonatal Hypoglycemia"; and last, myself.
2.0 Screem'ng for Neonatal Hypoglycemia
In discussing a rapid simple and useful clinical approach to
detect hypoglycemia, first, it i s necessary to screen those
infants at highest rlsk, uti l izing either the Dextrostix® or
Chemstrip® bG. Routine screening may be done at l, 2, 4, 6, 12,
24 and 48 hours of age (l, 2). The high risk infants to be
screened include all less than the 3rd or lOth (S.G.A.) or greater
than the 95th (L.G.A.) percentile for weight, the smaller of
discordant twins, infants of Insul in dependent or gestational
diabetic mothers, severe erythroblastotics, isolated hepatomegaly
or a positive family history of a sib with neonatal hypoglycemia
or an unexplained neonatal death. Early screening i s also
indicated in infants with significant anoxia or perinatal distress
(e.g. Apgar scores of < 5 at l minute) and in A.G.A. or L.G.A.
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babies either with exomphalos, macroglossia and gigantism
(Beckwith-Weidman Syndrome) or with a microphallus and/or a
congenital midi ine defect.
If the Dextrostix® or Chemstrip® are low and the infant
asymptomatic, a blood or serum glucose is measured in the clinical
chemistry laboratory. If significantly low (< 30 mg/dl in term, <
20 mg/dl LBW) , an intravenous infusion of glucose (6 to 8
mg/kg/min) should be given to restore the glucose values to
normal. This group represents about 50% of neonates with
hypoglycemia (2).
If clinical manifestations such äs tremors ("jitteriness"),
limpness, episode of cyanosis, apnea, irregulär respirations, an
abnormal cry, irritability, apathy or seizures occur in any
infant, screen the blood sugar at once. If low, obtain a blood
sample for a laboratory glucose analysis while starting the
intravenous glucose (ORAL GLUCOSE IS NOT THERAPY). If the
laboratory glucose i s low and the Symptoms clear fol lowing
intravenous glucose, the diagnosis of symptomatic hypoglycemia i s
verified. This group represents about 15% of neonatal
hypoglycemia.
If Symptoms persist or fail to clear completely even after
correction of hypoglycemia, a search must be made for other
underlying or associated pathology. This is critical since
hypoglycemia may be secondary to central nervous System pathology
(congenital defects, infections, hemorrhage or kernicterus),
sepsis, hydrops fetalis, congenital heart disease, asphyxia,
anoxia, adrenal hemorrhage, hypothyroidism, multiple congenital
anomalies, neonatal tetany and iatrogenic factors i.e., cold
injury, post-exchange transfusion, drugs to mother, or the abrupt
cessation of hypertonic parenteral glucose. This is especially
important in infants born to mothers taking narcotics or oral
hypoglycemic agents or being given beta adrenergic agents to
inhibit premature labor. These infants represent about 35% of
neonatal hypoglycemics.
If the Symptoms clear with intravenous glucose, but then tend
to recur or if the low blood glucose values persist in the
presence of adequate intravenous glucose (10-12 mg/kg/min) one
must consider the possibility of hyperinsulinism, hypopituitarism
or a metabolic defect. These represent the rare 1-2% of neonatal
hypoglycemics who are L.G.A. or A.G.A. and especially at h igh ,
risk. In these, the critical diagnostic blood sample must be
obtained both before and after glucagon (3) for measurements öf
glucose ketones, FFA, lactate, alanine, uric acid, insu!in, HGH,
cortisol, glucagon, and T4, $9 TSH.
After these critical blood samples are obtained, a
diagnostic-therapeutic trial is initiated and given sequentlally
without discontinuing the previous therapy. This includes: (1)
increased rates of glucose administration to 12-14 mg/kg/min, (2)
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Prednisone (2 mg/kg/day) or hydrocortlsone (15 mg/kg/day), (3) HGH
l u/day, (4) Diazoxide® 10-25 mg/kg/day, and (5) Surgery (2) .
Hyperinsulinism - If the infant i s large (60% are greater
than 95th percentile); the .hyperglycemic response to glucagon
exceeds 40 mg/dl (3); the urine ketones are negative; and the
blood ketones, F.F.A. and glucose are all Iow in the presence of a
relatively elevated plasma Insul in (> 12 yU/ml) (4) , then beta
cell pathology (hyperinsulinism) i s the likely diagnosis.
If the infant i s AGA or LGA (> 95th percentile in 25%), has a
microphallus (males), midline defect, jaundice, hepatomegaly, Iow
T4, Iow growth hormone (HGH) and resistant hypoglycemia,
congenital hypopituitarism is likely. Correction of hypoglycemia
occurs after Cortisol and/or HGH therapy i s added. The
hyperglycemic response to glucagon may be diminished or normal.
In a normal (AGA) or small (SGA) newborn, the presence of a
metabolic acidosis, jaundice, hepatomegaly and elevated uric acid;
reducing sugars, but no glucose, in the urine and ketonuria should
suggest an inborn error in carbohydrate or amino acid
metabolism. These include glycogen storage disease, galactosemia,
FDPase deficiency, tyrosinemia, or maple syrup urine disease. A
diminished (< 25 mg/dl) or absent hyperglycemic response to
glucagon i s characteristic of these infants.
The outcome in neonatal hypoglycemics depends upon proper
diagnosis, early treatment, and the associated äs well äs the
primary pathology. The prognosis for infants with severe
recurrent or persistent hypoglycemia remains guarded. While l i fe
may be spared, the long term outcomes of infants following
pancreatectomy, prolonged Diazoxide® therapy, and hormone
replacement for congenital hypopituitarism are just being
accumulated and await future analysis.
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